Case Report
Copyright ©The Author(s) 2023.
World J Clin Cases. Aug 6, 2023; 11(22): 5329-5337
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5329
Table 1 Reported cases of gastric cancer including hepatoid adenocarcinoma and neuroendocrine components
Ref.
Rassidakis et al[60]
Okamoto et al[61]
Suzuki et al[62]
Lipi et al[63]
Wincewicz et al[64]
Li et al[65]
Current case
Age48788350736061
SexManWomanManManWomanManMan
TNM stageN3T3N2M0T4N2M1N3T3N3M1T2N1MxT3N2M0
Tumor locationAnterior wall of the gastric bodyPyloric antrumUpper-third of the stomachCardiaGastric antrumGastric antrum
Tumor size70 mm × 55 mm90 mm × 60 mm × 30 mm75 mm × 110 mm85 mm × 65 mm × 45 mm60 mm × 40 mm16 mm20 mm × 15 mm × 5 mm
Histologic patternsHAC, NEDHAC, NEC, TACHAC, NEC, TACHAC, LCNEC, TACHAC, NED, OGCsHAC, NEDHAC, NED
ImmunohistochemistryCGA, AFPCK8, AE1/AE3, AFP, CGACGA, AFP, SPAFP, Syn, CGA, CKCGA, AFP, AE1/AE3, CKAFP, Syn, CGASALL4, AFP, GPC-3, Syn, CgA
SurgeryTotal gastrectomySubtotal gastrectomy with lymphadenectomyGastrectomyTotal gastrectomyR2 radical gastrectomyDistal gastrectomy with D2 lymphadenectomy
TreatmentDoxorubicin, mitomycin-C, 5-fluorouracil, octreotide (4 cycles)Cisplatin + VP 16 (2 cycles)Docetaxel + oxaliplatin + capecitabine (10 cycles), irinotecan + S-1 + apatinib (3 cycles)
AFP, ng/mL800 (post-op)168 (pre-op)1683 (pre-op)
OutcomeAlive, 12 mo Died, 53 mo, liver recurrenceDied, 6 moLiver recurrenceAlive, 6 moDied, 27 mo, liver recurrence